Survodutide Phase III data show 34% visceral and 63% liver fat cuts
Boehringer Ingelheim has reported detailed Phase III results for survodutide, its glucagon/GLP-1 receptor dual agonist, across two separate obesity trials presented at the American Diabetes Association's 2026 Scientific Sessions in New Orleans and simultaneously published in The New England Journal of Medicine and Nature Medicine. The data advance the case for survodutide as a metabolically targeted weight-loss agent, with visceral and liver fat reductions that go substantially beyond simple body-weight reduction.
Zealand Pharma, which licensed survodutide to Boehringer Ingelheim and retains royalty rights in the high single to low double-digit percentage range plus up to EUR 315 million in outstanding milestones, announced the results from Copenhagen.
SYNCHRONIZE-1: fat composition analysis
The 76-week SYNCHRONIZE-1 trial enrolled 725 adults with obesity or overweight who did not have type 2 diabetes. Previously announced topline results showed average weight loss of up to 16.6% using the efficacy estimand, against 3.2% for placebo (p<0.0001). The detailed sub-study data released at ADA add granularity: MRI-assessed visceral fat fell by up to 34.0% relative to baseline, and liver fat content dropped by up to 63.1%. Critically, lean mass accounted for no more than 10.8% of the change in total tissue mass at the highest dose (6.0 mg weekly), suggesting that the bulk of weight reduction was adipose rather than muscle. Gastrointestinal adverse events — nausea, vomiting, diarrhoea, and constipation — were the most common side effects, with a 19% discontinuation rate due to GI events compared with 2.9% on placebo.
David Kendall, Chief Medical Officer of Zealand Pharma, said the results "reinforce the potential of survodutide as a truly differentiated incretin-based therapy," adding that "there is a real need to improve metabolic health and move beyond blunt force weight reduction."
SYNCHRONIZE-MASLD: liver endpoints met
The 48-week SYNCHRONIZE-MASLD trial, which enrolled 218 adults with obesity or overweight and confirmed metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation or fibrosis, met both co-primary endpoints. Up to 84.2% of survodutide-treated participants achieved at least a 30% relative reduction in liver fat (vs 24.3% placebo; p<0.0001), and body weight fell by up to 12.2% versus 1.0% for placebo. A secondary endpoint showed 61.0% of treated patients reached liver fat normalisation (content below 5%) at week 48, compared with 5.7% on placebo. ALT reductions signalled reduced hepatic inflammation. No new safety signals were identified.
Competitive and regulatory context
The obesity and MASLD pharmacotherapy landscape is intensely competitive. Semaglutide (Novo Nordisk) and tirzepatide (Eli Lilly) have set high bars on weight reduction, with tirzepatide showing approximately 20–22% body-weight loss in SURMOUNT trials. Survodutide's differentiation argument rests on the glucagon receptor component, which is believed to act directly on the liver to reduce hepatic fat and address inflammation — a mechanism GLP-1 mono-agonists do not replicate to the same degree. How durable that positioning proves commercially will depend in part on forthcoming data from resmetirom (Madrigal Pharmaceuticals), the only currently approved agent specifically for MASH, and from competing dual and triple incretin programmes.
On the regulatory side, survodutide holds FDA Breakthrough Therapy designation for MASH with fibrosis, FDA Fast Track designation, EMA PRIME scheme acceptance, and breakthrough designations in China and Taiwan — a suite of designations that should facilitate rolling review conversations and expedite development timelines. Two further Phase III trials — LIVERAGE and LIVERAGE-Cirrhosis — are ongoing in MASH patient populations with fibrosis stages 2–4. A Phase IIIb programme is also expanding into women's health (SYNCHRONIZE-HERA), cardiac outcomes in MASLD (ELEVATE-LIVER), and real-world titration strategies (SYNCHRONIZE-START), with all three studies due to initiate later in 2026. Regulatory submissions remain some way off, but the breadth of the evidence programme positions survodutide as a credible long-term competitor in what is becoming one of the most commercially significant therapeutic categories in the industry.